Angioplasty

LimFlow Appoints Jenny Gaffney as Vice President, Health Economics and Reimbursement

Retrieved on: 
화요일, 8월 23, 2022
Medical Devices, Health, Diabetes, Health Technology, General Health, Cardiology, Mortality, Chronic pain, Artery, University, Degenerative disease, Obesity, Chronic limb threatening ischemia, Government, University of Michigan School of Information, Amputation, Ageing, Disease, Angioplasty, Sale, Public health, Leg, Policy, PAD, Economics, Vein, Kidney disease, Quality of life, Infection, Health policy, Harvard University, Patient, Prevalence, Wound healing, Population, Peripheral artery disease, Perfusion, Avalere Health, University of Michigan School of Public Health, Diabetes, Face, Coronary artery disease, Foot, CE marking, Pharmaceutical industry, Medical imaging, Medtronic

LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the appointment of Jenny Gaffney as Vice President, Health Economics and Reimbursement.

Key Points: 
  • LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the appointment of Jenny Gaffney as Vice President, Health Economics and Reimbursement.
  • Prior to joining LimFlow, she worked with Medtronic for more than seven years, most recently as the global lead for reimbursement and health economics for the coronary and renal denervation division.
  • Prior to Medtronic, she served as a healthcare policy and reimbursement consultant at Avalere Health, a premier Washington, DC-based firm.
  • in government, economics and health policy from Harvard University, and holds an executive masters degree in health management and policy from the University of Michigan School of Public Health.

Shockwave Medical Reports Second Quarter 2022 Financial Results

Retrieved on: 
월요일, 8월 8, 2022
Animation, Telephone, Cardiovascular disease, U.S. Securities and Exchange Commission, Organizational culture, Angioplasty, Moyamoya disease, GLOBE, Forward-looking statement, Technology, Private Securities Litigation Reform Act, Growth, SEC, Investment, Artery, Security (finance), Research, Annual report, Income, Patient, COVID-19, IVL, Disrupt, Risk, Plaque, Nasdaq, Adoption, Medical device, Video game, Pharmaceutical industry, Shock wave

Gross profit for the second quarter of 2022 was $104.0 million compared to $46.0 million for the second quarter of 2021.

Key Points: 
  • Gross profit for the second quarter of 2022 was $104.0 million compared to $46.0 million for the second quarter of 2021.
  • Gross margin for the second quarter of 2022 was 86%, as compared to 82% in the second quarter of 2021.
  • Total operating expenses for the second quarter of 2022 were $74.4 million, a 61% increase from $46.2 million in the second quarter of 2021.
  • Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Monday, August 8, 2022, to discuss its second quarter 2022 financial results.

David's Bridal Partners with Celebrity Fashion Designer DanielXDiamond to Launch Limited-Edition Jacket Collab at First-Annual NashBlast Event in Nashville

Retrieved on: 
화요일, 8월 2, 2022
Sale, Angioplasty, Bachelor, Rustic, Twitter, Social media, TikTok, Dry House Creek, Belle Meade, David's Bridal, Pulse, Mirror Ball (Neil Young album), Dream, Bachelorette, Pinterest, Courage, Daniel, Spice Girls, Television, RSVP, Spice, Creativity, YouTube, LinkedIn, Life, ABC, The Bride Show, Mark (given name), Mirror ball, Pharming, Dance, Nightclub, Dressmaker, Fashion, Interior design, Instagram, Sparrow, Facebook

CONSHOHOCKEN, Pa., Aug. 2, 2022 /PRNewswire/ -- David's Bridal, the nation's leading bridal and special occasion authority, has joined forces with celebrity fashion designer DanielXDiamond known for their coveted statement pieces for A-list entertainers, to release an exclusive custom denim fringe jacket tailored for all of life's magical moments. The jacket turns the world into a runway. From bachelorette parties to girls' night out, this limited-edition collaboration is the perfect addition to every stand-out wardrobe.

Key Points: 
  • "At David's Bridal we believe in celebrating all of life's magical moments," said Kelly Cook, Chief Marketing & IT Officer of David's Bridal.
  • "We wanted to debut this must-have bridal accessory during the peak of bachelorette season in the epic bachelorette destination of Nashville, Tennessee.
  • With the help of Kaitlyn and DanielXDiamond, David's Bridal will also host a live TikTok shopping experience during the NashBlast party.
  • Customers from all over can join the live virtual shopping party to snag their own coveted David's Bridal and DanielXDiamond fringe jacket.

Centers for Medicare & Medicaid Services (CMS) Issue New ICD-10-PCS Code for ZOLL Medical's TherOx SSO2 Therapy

Retrieved on: 
목요일, 7월 14, 2022
Research, General Health, Professional Services, Pharmaceutical, Technology, Medical Devices, Hospitals, Science, Biotechnology, Insurance, FDA, Other Technology, Health, Health care, Ammonia, Data management, Life, Health information management, LAD, Solution, Asahi Kasei, Infarction, EMS, Muscle tissue, Atherosclerosis Risk in Communities, Patient, Supersaturation, Center, Institute for Community Studies, Mortality, Centers for Medicare & Medicaid Services, CPR, CMS, Diagnosis, STEMI, Cardiac muscle, Data collection, Medicare, Health, Angioplasty, Epidemiology, Atherosclerosis, FDA, Research, Hamad Medical Corporation, Hospital, Dialysis, Ventilation, Risk, Myocardial infarction, Sleep apnea, Classification, Pharmaceutical industry, Medical device

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination and Maintenance Committee has issued a new ICD-10-PCS code for TherOx SuperSaturated Oxygen (SSO2) Therapy.

Key Points: 
  • ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination and Maintenance Committee has issued a new ICD-10-PCS code for TherOx SuperSaturated Oxygen (SSO2) Therapy.
  • The new code (5A0222C), for cardiac intra-arterial use, is effective for hospital discharges beginning October 1, 2022.
  • The code includes treatment of patients with left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attacks, which have higher mortality rates than other types of heart attacks.
  • TherOx and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.

Continued Clinical Success Reported with Unique Cutting-Edge Vessel Prep Device

Retrieved on: 
목요일, 6월 30, 2022
CE marking, Fistula, FDA, Tri-City Medical Center, View, Patient, PTA, Multimedia, Hyperplasia, Angioplasty, CE, Dissection, Technology, Dural arteriovenous fistula, CS, PARK, XO, ATM, Dilation, Stenosis, Aluminium, Natural rubber, Medical device

PARK CITY, Utah, June 30, 2022 /PRNewswire/ -- Transit Scientific shares successful outcomes on multiple fistula and graft cases using its XO Score Sheath Platform along with off-the-shelf percutaneous transluminal angioplasty (PTA) balloons.

Key Points: 
  • First-of-its-kindmetal-alloy scoring, cutting, and constraining structure (CS) device continues to elevate angioplasty treatment of chronic dialysis fistulas and grafts.
  • The lesion was resistant to initial treatment using a high-pressure PTA inflated to 40 atmospheres (ATM).
  • The lesion was then treated with the XO Scoredevice and followed by effacement of the stenosis with standard balloon PTA inflated to nominal pressure (9ATM).
  • When the angioplasty balloon is inflated, the struts/grooves expand with the balloon and rotate 90 to apply focal force to the vessel.

Advanced NanoTherapies Announces Closing of Oversubscribed $7.2 Million Series A Financing

Retrieved on: 
화요일, 6월 28, 2022
CAD, Time Machine, Patient, Director, CEO, Trial of the century, Ministry of Education (Malaysia), API, Restenosis, Multimedia, De novo, Peripheral artery disease, ANT, DCB, Risk, Angioplasty, Active ingredient, PAD, Entrepreneurship, Associate, American College, University Hospitals Cleveland Medical Center, Coronary artery disease, LOS, MD, Nanotechnology, Pharmaceutical industry, Medicine, Sirolimus, Paclitaxel

LOS GATOS, Calif., June 28, 2022 /PRNewswire/ -- Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease's most significant challenges through the creative applications of nanotechnology, today announced the closing of its oversubscribed $7.2 million Series A equity financing, marking a total of $12.5 million raised since September 2020. Funds will be used to complete the first-in-human clinical study in Australia of the SirPlux Duo drug-coated balloon (DCB) in de-novo coronary artery disease (CAD) lesions. Funding comes from various sources in the U.S., Canada, Europe, and Asia.

Key Points: 
  • LOS GATOS, Calif., June 28, 2022 /PRNewswire/ -- Advanced NanoTherapies , Inc., a privately-held medical device company committed to solving vascular disease's most significant challenges through the creative applications of nanotechnology, today announced the closing of its oversubscribed $7.2 million Series A equity financing, marking a total of $12.5 million raised since September 2020.
  • "Interventional therapies have historically advanced in big steps angioplasty, bare-metal stenting, drug-eluting stenting," saysReggie Groves, Board of Directors Member at Advanced NanoTherapies.
  • We are pleased toinitiatethe next phase of Advanced NanoTherapies' clinical program."
  • Advanced NanoTherapies, Inc. is a highly specialized medical device company developing a nanoparticle technology-based platform for drug delivery.

Cagent Vascular Announces Commercial Launch of the Serranator Above-the-Knee (ATK) Product

Retrieved on: 
수요일, 6월 1, 2022
General Health, Medical Devices, Health, Other Technology, Technology, Community, Life, Economic development, Elective surgery, Mount Sinai Hospital, Pressure, Standard of care, Artery, Dissection, CEO, Pennsylvania Department of Community and Economic Development, Physician, Sale, Cardiovascular disease, Patient, Technology, BTK, Adoption, ATK, MD, Economy, Angioplasty, Miriam Hospital, Pharmaceutical industry, Fernand Serrane

Cagent Vascular launched the Serranator Below-the-Knee (BTK) product in January 2021.

Key Points: 
  • Cagent Vascular launched the Serranator Below-the-Knee (BTK) product in January 2021.
  • Since then, there has been rapid adoption at targeted centers, where Serranator is quickly becoming the standard of care.
  • The Serranator PTA Serration Balloon Catheter is an angioplasty device with serrated metal strips embedded on a semi-compliant balloon.
  • Expanding into the ATK segment will generate significant incremental revenue and build upon our success from last years BTK product launch where the Serranator was used as the primary therapy.

Global Pediatric Interventional Cardiology Market Research Report 2022-2027: Industry Trends, Share, Growth, Impact of COVID-19, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
월요일, 5월 30, 2022
Health, Other Health, Cardiology, Stenosis, Incidence, SCSI Peripheral Device Type, Siemens, Patient, Investment, Association, Boston Scientific, D, COVID-19, Industry, General Electric, Congenital heart defect, Awareness, Medtronic, Cardinal Health, Hospital, Technology, Attention, Angioplasty, CAGR, Diagnosis, Abbott Laboratories, Cardiology, Medicine, Medical imaging, Growth

The "Pediatric Interventional Cardiology Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pediatric Interventional Cardiology Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Pediatric Interventional Cardiology Market is estimated to reach US$ 2,190.1 Million by 2027, from US$ 1,510.3 Million in 2021.
  • Global Pediatric Interventional Cardiology Industry is anticipated to expand at a CAGR of 6.39% during 2021-2027:
    The global Pediatric Interventional Cardiology Market Size is expanding rapidly, owing to a growth in the number of children with cardiac disorders and technical breakthroughs in the area.
  • The Hospitals Segment Dominates the Market for Global Pediatric Interventional Cardiology Devices:
    The hospital segment will lead the Paediatric Interventional Cardiology Devices market in 2021 and beyond.

PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions

Retrieved on: 
금요일, 5월 20, 2022
Physician, Risk, Pain, Intervention, Company, Cardiology, Aspirin, Patient, NASDAQ, Review, API, Corporate communication, Stomach, Patent, FDA, Awareness, SCAI, Pharma, OBI Pharma, Inc., Faculty, Therapy, Society, PLX, Angioplasty, Fortis Healthcare, ASA, MD, Absorption, Cardiovascular disease, GLOBE, Pharmaceutical industry, Generic drug

The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as VAZALORE), today announced that it is participating in the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI) during May 19 22, 2022 in Atlanta, GA.

Key Points: 
  • The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as VAZALORE), today announced that it is participating in the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI) during May 19 22, 2022 in Atlanta, GA.
  • Through the Companys efforts to build awareness and advocacy for VAZALORE among healthcare professionals, including interventional cardiologists, it will prominently display VAZALORE during the SCAI annual meeting.
  • The Company will also provide product samples and educational materials to the attending faculty, cardiologists, and fellows.
  • To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com .

Huntington Medical Research Institutes Present First-of-its-Kind Study Examining Impact of Erectile Dysfunction Drugs on Major Adverse Cardiovascular Events and Mortality

Retrieved on: 
금요일, 5월 13, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Men, Health, Consumer, Placebo, MBA, Death, Lists of diseases, ED, Huntington Medical Research Institutes, Population, HMRI, Nationwide Mutual Insurance Company, Tadalafil, Degenerative disease, Doctor of Philosophy, Patient, Migraine, American Heart Association, Solution, Association, Causality, Sildenafil, University of California, San Francisco, American Heart, Vardenafil, Medicare, San Francisco, Research, Erectile dysfunction, Brain, Man, University, Heart failure, Mortality, Heart, Care, Unstable angina, Tablet, Coronary artery disease, Angioplasty, Record, MD, CEO, Pharmaceutical industry, Dietary supplement, Sanofi

Scientists from Huntington Medical Research Institutes (HMRI) in Pasadena, HealthCore Inc. and the University of California San Francisco analyzed health records of more than 70,000 men with ED.

Key Points: 
  • Scientists from Huntington Medical Research Institutes (HMRI) in Pasadena, HealthCore Inc. and the University of California San Francisco analyzed health records of more than 70,000 men with ED.
  • They compared rates of major adverse cardiovascular events (MACE) and death amongst men who took phosphodiesterase type 5 inhibitor (PDE-5i) drugsincluding Viagra, Cialis and Levitrato rates among men who never took these drugs.
  • Since the study was retrospective, Kloner noted that further research is needed to prove that PDE-5i drugs caused the reduction in cardiovascular events that he and his co-investigators observed.
  • Huntington Medical Research Institutes (HMRI) works to improve millions of lives through patient-focused scientific research.